In the current study, we focused on β-catenin expression and transactivation since mutations in APC tumor suppressor genes are observed in 90% of colon cancer patients, and the end point of this mutation results in the activation of β-catenin transcriptional activity in human colon cancers. This evidence concerns the gene APC and colonic neoplasm.